Pareto Securities' Healthcare Conference: Cinclus Pharma is trying to usher in the next generation of acid reflux medicines with linaprazan glurate, a potassium-competitive acid blocker (P-CAB)

Sep 16, 2025
1 min read

CEO Christer Ahlberg describes the shortcomings of today's medicines, and why he believes a P-CAB is the answer. This therapy originated at AstraZeneca, though Cinclus owns it outright today, and is in a phase 3 that just started.

https://vimeo.com/1119170271?share=copy

Coverage brought to you by:

Recent Posts

See All

LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants

From NYSE: Noetik has been building a large database from patient tumor samples to use AI to help understand which patients are more likely to respond to medicines in the future

From NYSE: Alloy Therapeutics, which has a service provider model of helping other companies develop therapies, recently crossed the $1B valuation mark on their series E and is now fully integrated

Pareto Securities' Healthcare Conference: Cinclus Pharma is trying to usher in the next generation of acid reflux medicines with linaprazan glurate, a potassium-competitive acid blocker (P-CAB)

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight